Osteoblasts play a critical role in the maintenance of bone mass through bone formation and regulation of bone resorption. Targeted expression of a constitutively active engineered G i -coupled G protein-coupled receptor (GPCR) to osteoblasts in vivo leads to severe osteopenia. However, little is known about the role of endogenous receptor-mediated G i signaling in regulating osteoblast function. In this study, we investigated the skeletal effects of blocking G i -coupled signaling in osteoblasts in vivo. This was accomplished by transgenic expression of the catalytic subunit of pertussis toxin (PTX) under control of the collagen Ia 2.3-kb promoter. These mice, designated Col1(2.3)
Introduction
G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors, and as such, they mediate a host of cellular responses. GPCRs have been very fruitful therapeutic targets, with over 25% of drugs approved by the Food and Drug Administration acting directly on members of this receptor family.
(1) GPCRs continue to be common targets of newly developed pharmaceuticals, and furthering our understanding of the biologic role of GPCRs still holds promise for the development of new therapeutics. Four families of Ga proteins are critical in mediating signaling downstream of GPCR activation: G s , G i , G q , and G 12 . (2) A role for G s -coupled signaling in osteoblasts in promoting trabecular bone formation and cortical bone resorption has been described in vivo in both gainof-function and loss-of-function models. (3) (4) (5) (6) The role of the other families of Ga proteins in the regulation of skeletal homeostasis remains less clear. The classic downstream effector of G i activation is the inhibition of adenylyl cyclase, (2) which would be expected to antagonize G s -mediated increases in adenylyl cyclase activity in osteoblasts. Transgenic expression of a constitutively active G i -coupled GPCR in osteoblasts leads to marked trabecular osteopenia, (7) consistent with the concept of G i -coupled signaling opposing G s -mediated trabecular bone formation. However, the role of endogenous G i -coupled receptors in regulating osteoblast function is less clear. A range of ligands has been shown to elicit G i -dependent mitogenic responses from osteoblastic cells in vitro. These ligands include fluoride, (8) lysophosphatidic acid, (9) and spingosine 1-phosphate. (10) Additionally, activation of the G i -coupled apelin receptor stimulates proliferation and inhibits apoptosis of human osteoblasts in vitro. (11, 12) Such mitogenic effects may be mediated by alternative effectors of G i -coupled signaling such as mitogenactivated protein kinases (MAPKs) and phosphoinoisitide-3 kinase (PI3K). (13, 14) Two candidate GPCRs have been suggested as potential targets for osteoporosis therapeutic strontium ranelate (15, 16) : the calcium-sensing receptor (CaSR) (17, 18) and the closely related GPRC6A. (19) Both these GPCRs can couple with both G i and G q , (20) (21) (22) suggesting that the in vivo anabolic actions of strontium could, at least in part, be mediated by stimulation of G i signaling. Genetic manipulation of endogenous G i -coupled GPCRs in mice has given rise to a range of skeletal phenotypes. Recently, the G i -coupled serotonin receptor Htr1b has been described as a negative regulator of osteoblast proliferation, with global and osteoblast-specific gene deletion of Htr1b leading to increased vertebral bone volume associated with increased osteoblast number. (23) The global knockout of the NPY Y1
receptor also shows increased cancellous bone volume that is proposed to result from loss of osteoblastic Y1 expression. (24) Conversely, deletion of the gene encoding the G i -coupled CB2 cannabinoid receptor led to accelerated age-related bone loss, and a CB2-specific agonist was found to attenuate bone loss induced by estrogen deficiency in mice. (25) There are, of course, limitations to interpreting phenotypes resulting from global gene deletions, and the marked difference in the skeletal phenotypes of the Htr1b À/À and CB2 À/À mice may be due in part to differences in expression of these two receptors both within the osteoblast lineage and in other cell types. Additionally, the contexts in which osteoblasts are exposed to the ligands for these two receptors may differ significantly. Furthermore, if osteoblasts at different stages of the osteoblast lineage have altered responses to G i -coupled signaling, this potentially could reconcile the mitogenic effects of activation of G i -coupled receptors on osteoblastic cells in vitro with the restriction of osteoblast proliferation by the G i -coupled Htr1b in vivo.
In this study, we have pursued a strategy of osteoblast-specific blockade of G i -coupled signaling in order to further elucidate the role of this signaling pathway in regulating osteoblast function. G i -coupled signaling is mediated by a family of Ga i subunits (Ga i1 , Ga i2 , Ga i3 , Ga o , Ga z , the retinal a subunit Ga t , and the taste a subunit Ga gust ) (2) and so cannot easily be eliminated using gene-deletion technology. However, GPCRmediated activation of the most ubiquitous and abundant Ga i subunits (Ga i1 , Ga i2 , Ga i3 , and Ga o ) is inhibited by pertussis toxin, and this agent therefore is used widely in vitro as a tool to identify G i -mediated effector responses. Here we have used osteoblast-specific expression of the catalytic subunit of pertussis toxin in vivo to probe the role of receptor-mediated G i signaling in these cells.
Materials and Methods
Mouse studies 
Quantitative static histomorphometry
Femurs from 12-week-old mice were isolated at the time of euthanasia and fixed in 10% NBF for 1 to 2 days and stored in 70% ethanol. Following mCT analysis, the undecalcified bone samples were embedded in methyl methacrylate and sectioned with Jung 2065 and 2165 microtomes (Leica, Bannockburn, IL, USA). Osteoblast and osteoclast surfaces in the secondary spongiosa of the distal femoral metaphysis were measured in von Kossa/tetrachrome-stained sections with an Osteomeasure System (Osteometrics, Decatur, GA, USA) as described previously. (26) Dynamic histomorphometry
Mice were injected with 20 mg/kg of calcein (Sigma-Aldrich, St Louis, MO, USA) 21 and 7 days before euthanasia and with 15 mg/kg of demeclocycline (Sigma-Aldrich) 2 days before euthanasia. Mice were euthanized at 8 weeks, and femurs were isolated, fixed in 10% NBF, and stored in 70% ethanol. Following mCT analysis, the undecalcified bone samples were embedded in methyl methacrylate. Assessment of cancellous bone was performed on 10-mm longitudinal sections from the left femur. Assessment of cortical bone was performed on 10-mm transverse sections at the midpoint of the right femur. Mosaic-tiled images were acquired at Â 20 magnification with a Zeiss Axioplan Imager M1 microscope (Carl Zeiss MicroImaging, Thornwood, NY, USA) fitted with a motorized stage. The tiled images were stitched and converted to a single image using the Axiovision software (Carl Zeiss MicroImaging) prior to blinded analyses being performed using image-analysis software (Bioquant Image Analysis Corp., Nashville, TN, USA). Cancellous bone was assessed in an irregular ROI defined by four boundaries: a line traced at a distance of 500 mm from the growth plate, two lines drawn parallel to the cortical bone at a distance of 200 mm from the endocortical surface, and a straight line drawn perpendicular to the bone at a distance of 1.7 mm from the lowest point of the growth plate. An average of 5.3 mm 2 of cancellous bone tissue (including marrow) was measured. The dynamic indices of bone formation that were measured include mineralizing surface, mineral apposition rate, and surface-based bone-formation rate (BFR/BS).
Serum chemistry
Blood was collected from mice at the time of euthanasia and processed in MicroTainer serum separator tubes (BD Biosciences, San Jose, CA, USA). Serum procollagen type I amino-terminal propeptide (PINP) and serum pyridinoline measurements were carried out using the rat/mouse PINP EIA Kit AC-33F1 from Immunodiagnostic Systems (Scottsdale, AZ, USA) and the MetraBiosystems SerumPYD Kit 8019 (MetaBiosystems, Santa Clara, CA, USA) according to manufacturers' directions.
Statistical analysis
All data are presented as means AE SD. Statistical significance was ascertained by comparison between Col1(2.3)-PTX mice and sexmatched littermate controls using a two-tailed Student's t tests assuming equal variance or, where indicated, by two-way ANOVA.
Results
Generation of mice with osteoblast-specific, tetracyclineregulated expression of the catalytic subunit of pertussis toxin PTX
In order to allow for the temporal control of PTX expression, we used the tetracycline transactivator (tTA) system (TetOff). (27, 28) To obtain spatial control, TetO-PTX transgenic mice were mated with transgenic mice expressing tTA under the control of the osteoblast-specific Col1a1 2.3-kb promoter fragment.
PTX expression was assessed in a range of tissues from 12-week-old
Col1(2.3)-tTA single-transgenic controls (Fig. 1A) . In animals maintained off doxycycline, expression of PTX is limited to long bones and calvaria, with some off-target expression in the lung. PTX expression was almost completely suppressed in mice maintained on a diet that contained doxycycline (Fig. 1B) . We observed large variation in PTX expression levels and examined the expression data by gender segregation (Fig. 1C) . Expression of PTX in bone from 12-week-old males was readily detectable but much lower than that observed for females. When PTX expression levels were assessed in younger animals (8 weeks), they were found to be much higher than in the 12-week-old animals, and the gender difference in expression levels was much less pronounced ( Fig. 1D ).
Effects of PTX expression on growth (Fig. 3B ). This phenomenon, which was observed in both male and female mice, was further examined by dynamic histomorphometry in 8-week-old animals. The dynamic labeling protocol for the 8-week-old mice was devised prior to full characterization of the femoral midshaft phenotype in younger animals and was designed to cover as broad a developmental period as possible. A dramatic increase in the periosteal bone-formation rate (BFR/BS) resulting from increased mineralizing surface was observed in Col1(2.3) þ /PTX þ mice when assessed using a 5-day labeling interval between a calcein label given at 7 weeks of age and a demeclocycline label given at 2 days before euthanasia (Table 1) . Similar results were observed using a longer labeling interval (calcein label given at 5 and 7 weeks of age; data not shown). 
Quantitation of endocortical bone formation gave less striking results. While there was a suggestion of increased endocortical mineralizing surface (significant only in females) and decreased endocortical MAR (significant only in males), no change in endocortical BFR/BS was observed ( Table 2) .
Effects of PTX expression on cancellous bone structure
To assess cancellous bone mass in Col1(2.3) þ /PTX þ mice, femurs from 12-week-old mice were examined using both mCT and histomorphometry. Assessment using mCT was used initially to evaluate a metaphyseal trabecular ROI immediately adjacent to the primary spongiosa: ROI1 (Fig. 4A) increase in BV/TV associated with increased trabecular number, decreased trabecular spacing, and no change in trabecular width (Fig. 4C) . When considering the contradictory nature of the mCT evaluation of ROI1 and histomorphometric analysis of the same bones, it was noted that the histomorphometric region of analysis was placed further from the growth plate than mCT ROI1. To account for this, the mCT scans were retrieved, and an ROI further from the growth plate, ROI2, was evaluated. The assessment of ROI2 was found to concur with the histomorphometric assessment. Male Col1(2.3) þ /PTX þ mice showed no significant changes in BV/TV, and female Col1(2.3)
had strikingly increased BV/TV (Fig. 4A) . The female-specific increase in BV/TV in ROI2 was associated with an increase in trabecular number, decrease in trabecular spacing, and increased connectivity density (Fig. 4B) (Fig. 5A ). These changes in osteoblast surface also did not correlate with the lack of alteration in the expression of osteoblast marker genes Runx2, osterix, and osteocalcin in RNA isolated from 8-week-old femurs (data not shown). Curiously, both male and female Col1(2.3)
Quantifiable amounts of osteoid are not typically observed in the mouse, and all control animals were assigned a minimum detectable osteoid volume of 0.1%, whereas osteoid was readily quantifiable in all samples of Col1(2.3)
Alterations in cellular morphology also were noted in both male and female Col1(2.3)
played a notable increase in plump osteoblast-like cells that were not directly associated with the bone surface both in the primary spongiosa ( Fig. 5F ) and in the secondary spongiosa (Fig. 5F ). This was particularly evident in the primary spongiosa, where in Col1(2.3) þ /PTX þ mice marrow elements were never observed within 100 mm of the growth plate. Marrow elements were readily observed in this region in control mice.
To assess whether the increased cancellous bone mass observed in female Col1 (2.3) þ /PTX þ mice could be due to increased osteoblast activity, dynamic histomorphometry was It has been shown previously that treatment of mice with the serotonin synthesis inhibitor pCPA leads to increased expression of cyclin D1, cyclin D2, and cyclin E1 in bone, presumably through reducing activation of the G i -coupled Htr1b receptor in osteoblasts. (23) Consequently, we examined the expression of these genes in RNA isolated from 8-week-old femurs in our model of osteoblast-specific G i signaling blockade. Cyclin D1 was significantly increased in both male and female Col1(2.3) þ /PTX þ mice, cyclin D2 showed a trend toward being increased in females, and no change was seen in cyclin E1 (Fig. 5E) . Effects of osteoblast-specific PTX expression on osteoclasts
Whereas osteoblasts have a well-appreciated role in regulating osteoclast number and activity, we saw little evidence suggesting that blockade of G i -coupled signaling in osteoblasts has downstream effects on osteoclasts. Histomorphometry revealed an increase in osteoclast surface only in Col1(2.3) þ /PTX þ males (Fig. 6A) . However, levels of serum pyridinoline cross-links, a marker of bone resorption, were unaltered in both male and female Col1(2.3) þ /PTX þ mice (Fig. 6B ). RANKL and osteoprotegerin (OPG) are important factors expressed by osteoblasts that regulate osteoclastogenesis. (29) Expression of RANKL and OPG and the ratio of RANKL/OPG expression remain unchanged by osteoblast-specific PTX expression in bone from 8-week-old femurs ( Fig. 6C and data not shown) . Similarly, expression of the calcitonin receptor, a gene highly expressed in osteoclasts, is unchanged in bone from Col1(2.3) þ /PTX þ mice (Fig. 6D ).
Discussion
For several decades, sensitivity to pertussis toxin has been the ''gold standard'' in determining the involvement of receptoractivated G i signaling in in vitro assays. Here we describe the osteoblast-specific, tetracycline-regulated expression of the S 1 catalytic subunit of pertussis toxin for the purpose of probing the role of this signaling pathway in vivo. Previously, transgenic expression of PTX has been used in vivo to assess the role of G i signaling in T cells, (30) and a model for Cre-inducible PTX expression has been demonstrated in pancreatic b cells. (31) Our model is unique in that it allows for the reversible regulation of PTX expression. For this to be significant, it is imperative that suppression of PTX expression by doxycycline is sufficient to ablate the functional enzymatic activity of PTX. Our observation that maintaining Col1(2.3) that osteoblasts at different sites may be distinguished from each other either by the complement of G i -coupled receptors that they express or by differential exposure to the ligands of these receptors. In fact, this may be one mechanism by which cortical drift, the differential regulation of bone formation at different cortical surfaces, is normally established. The phenomenon of cortical drift is poorly understood but is of clear importance in determining bone shape as well as bone volume. The role of cortical drift in regulating bone shape is recognized both during growth (32) (33) (34) and in response to mechanical stimuli. (35, 36) Col1(2.3) þ /PTX þ mice do not have gross deformities in bone development, patterning, or shape, but the altered pattern of bone formation does suggest that they will develop changes in femoral shape as they age. The effect of these changes on the biomechanical properties of the bone remains to be investigated.
Regional specificity of increases in bone formation also was observed in cancellous bone of Col1 (2. histomorphometrically assessed fractional bone volume, they are not completely devoid of a cancellous bone phenotype. We had hypothesized that the role of G i signaling in osteoblasts may be to antagonize increases in cAMP levels in response to G s -coupled signaling. If this were the case, blockade of receptor-mediated G i signaling in osteoblasts would be expected to yield a similar phenotype to models of increased G s signaling in osteoblasts. The phenotypes of transgenic mouse models with osteoblast-specific activation of G s -coupled signaling typically are characterized by increased trabecular bone formation, marrow fibrosis, and cortical bone resorption. (4) (5) (6) (5) contrast with the increased cortical thickness, periosteal mineralizing surface, and BFR/BS in the Col1(2.3) þ /PTX þ mouse.
Increased G s -coupled signaling in osteoblasts is also classically associated with increased RANKL expression and increased osteoclastogenesis and activity. We saw no increase in RANKL expression in bone and no indication of increased osteoclast activity in Col1(2.3) þ /PTX þ mice. These data suggest that while G s -coupled signaling in osteoblasts promotes bone formation and G i -coupled signaling in osteoblasts restricts bone formation, the downstream consequences of blockade of G i -coupled signaling in osteoblasts are not exclusively mediated by relieving inhibition of adenylyl cyclase-mediated production of the second-messenger cAMP. Our data suggest that receptor-activated G i signaling in osteoblasts acts as a site-specific constitutive negative regulator of bone and may be a therapeutic target. In recent years, another class of constitutive negative regulators of bone formation, the secreted Wnt inhibitors, has been fruitfully targeted in the search for anabolic therapies for osteoporosis. While there are many secreted Wnt inhibitors, they appear not to be functionally redundant, and antagonism of a single inhibitor yields increases in bone formation. Perhaps the same will be true for G i -coupled GPCRs, and identifying the full complement of G i -coupled GPCRs expressed in osteoblasts may reveal novel therapeutic targets. The G i -coupled serotonin receptor Htr1b is one such target, and suppression of gut-derived serotonin synthesis has shown promise in treating rodent models of postmenopausal bone loss. (37) Provided that the increased bone formation and bone volume associated with the blockade of G i -coupled signaling can be shown to correlate with increased bone strength, it represents a novel therapeutic target for the development of bone anabolic therapies.
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